

Home Layout Tables Charts SmartArt Formulas Data Review

Edit Font: Calibri 11 Alignment: General Number: General Format: Currency 2, Normal 2, Percent 2

Conditional Formatting: Normal, Bad, Good

Cells: Insert, Delete, Format

CASH FLOW STATEMENT AND NPV CALCULATIONS															
INDICATION 1	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028
Sales after launching	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 150,000,000.00	\$ 300,000,000.00	\$ 450,000,000.00	\$ 600,000,000.00	\$ 600,000,000.00
Manufacturing of sold goods	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,672,500.00	\$ 10,445,000.00	\$ 15,667,500.00	\$ 20,890,000.00	\$ 20,890,000.00
Gross profit	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 144,327,500.00	\$ 289,555,000.00	\$ 434,332,500.00	\$ 579,110,000.00	\$ 579,110,000.00
Clinical trial costs (clinical)	\$ 750,000.00	\$ 750,000.00	\$ 1,875,000.00	\$ 1,875,000.00	\$ 1,875,000.00	\$ 1,885,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ -	\$ -	\$ -	\$ -	\$ -
Clinical trial costs (manufacturing)	\$ 825,000.00	\$ 378,000.00	\$ 1,085,000.00	\$ 635,000.00	\$ 635,000.00	\$ 635,000.00	\$ 1,470,000.00	\$ 1,020,000.00	\$ 1,020,000.00	\$ 1,020,000.00	\$ -	\$ -	\$ -	\$ -	\$ -
Staff costs	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00
Estate / facility costs	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 150,000.00	\$ 150,000.00	\$ 150,000.00	\$ 150,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00
Sales and marketing costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00
Equipment/Logistic/Other costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00
EBIT (Earning before income tax)	\$ -3,040,000.00	\$ -2,593,000.00	\$ -4,425,000.00	\$ -3,975,000.00	\$ -3,975,000.00	\$ -3,985,000.00	\$ -7,295,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ 140,642,500.00	\$ 285,870,000.00	\$ 430,647,500.00	\$ 575,425,000.00	\$ 575,425,000.00
Taxable Income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 140,642,500.00	\$ 285,870,000.00	\$ 430,647,500.00	\$ 575,425,000.00	\$ 575,425,000.00
Corporate tax rate %	15%														
	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 21,096,375.00	\$ 42,880,500.00	\$ 64,597,125.00	\$ 86,313,750.00	\$ 86,313,750.00
EBIAT = Cash flow	\$ -3,040,000.00	\$ -2,593,000.00	\$ -4,425,000.00	\$ -3,975,000.00	\$ -3,975,000.00	\$ -3,985,000.00	\$ -7,295,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ 119,546,125.00	\$ 242,989,500.00	\$ 366,050,375.00	\$ 489,111,250.00	\$ 489,111,250.00
Terminal value															\$ 5,455,947.80
Discount value (R&D risk)	1	1.00	0.93	0.93	0.93	0.93	0.51	0.51	0.51	0.51	0.34	0.34	0.34	0.34	0.34
Discount value (cost of capital %)	25%	0.750	0.563	0.422	0.316	0.237	0.178	0.133	0.100	0.075	0.056	0.042	0.032	0.024	0.018
Discounted Cash Flows	\$ -2,280,000.00	\$ -1,458,562.50	\$ -1,736,121.09	\$ -1,169,674.80	\$ -877,256.10	\$ -659,597.28	\$ -498,080.77	\$ -350,517.09	\$ -262,887.82	\$ -197,165.86	\$ 1,730,333.60	\$ 2,637,807.56	\$ 2,980,284.48	\$ 2,986,659.96	\$ 2,239,994.97
Net Present Value	\$ 8,541,165.05														
	Run Scenario Analysis		Click Here To Calculate For A Different Project												

Home Layout Tables Charts SmartArt Formulas Data Review

Edit Font: Calibri 11 Alignment: General Number: General Format: Currency 2, Normal 2, Percent 2

Conditional Formatting: Normal, Bad, Good

Cells: Insert, Delete, Format

CASH FLOW STATEMENT AND NPV CALCULATIONS															
INDICATION 1	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028
Sales after launching	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 150,000,000.00	\$ 300,000,000.00	\$ 450,000,000.00	\$ 600,000,000.00	\$ 600,000,000.00
Manufacturing of sold goods	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,672,500.00	\$ 10,445,000.00	\$ 15,667,500.00	\$ 20,890,000.00	\$ 20,890,000.00
Gross profit	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 144,327,500.00	\$ 289,555,000.00	\$ 434,332,500.00	\$ 579,110,000.00	\$ 579,110,000.00
Clinical trial costs (clinical)	\$ 750,000.00	\$ 750,000.00	\$ 1,875,000.00	\$ 1,875,000.00	\$ 1,875,000.00	\$ 1,885,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ -	\$ -	\$ -	\$ -	\$ -
Clinical trial costs (manufacturing)	\$ 825,000.00	\$ 378,000.00	\$ 1,085,000.00	\$ 635,000.00	\$ 635,000.00	\$ 635,000.00	\$ 1,470,000.00	\$ 1,020,000.00	\$ 1,020,000.00	\$ 1,020,000.00	\$ -	\$ -	\$ -	\$ -	\$ -
Staff costs	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00
Estate / facility costs	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 150,000.00	\$ 150,000.00	\$ 150,000.00	\$ 150,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00
Sales and marketing costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00
Equipment/Logistic/Other costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00
EBIT (Earning before income tax)	\$ -3,040,000.00	\$ -2,593,000.00	\$ -4,425,000.00	\$ -3,975,000.00	\$ -3,975,000.00	\$ -3,985,000.00	\$ -7,295,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ 140,642,500.00	\$ 285,870,000.00	\$ 430,647,500.00	\$ 575,425,000.00	\$ 575,425,000.00
Taxable Income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 140,642,500.00	\$ 285,870,000.00	\$ 430,647,500.00	\$ 575,425,000.00	\$ 575,425,000.00
Corporate tax rate %	15%														
EBIAT = Cash flow	\$ -3,040,000.00	\$ -2,593,000.00	\$ -4,425,000.00	\$ -3,975,000.00	\$ -3,975,000.00	\$ -3,985,000.00	\$ -7,295,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ 119,546,125.00	\$ 242,989,500.00	\$ 366,050,375.00	\$ 489,111,250.00	\$ 489,111,250.00
Terminal value															\$ 5,455,947.80
Discount value (R&D risk)	1	1.00	0.93	0.93	0.93	0.93	0.51	0.51	0.51	0.51	0.34	0.34	0.34	0.34	0.34
Discount value (cost of capital %)	25%	0.750	0.563	0.422	0.316	0.237	0.178	0.133	0.100	0.075	0.056	0.042	0.032	0.024	0.018
Discounted Cash Flows	\$ -2,280,000.00	\$ -1,458,562.50	\$ -1,736,121.09	\$ -1,169,674.80	\$ -877,256.10	\$ -659,597.28	\$ -498,080.77	\$ -350,517.09	\$ -262,887.82	\$ -197,165.86	\$ 1,730,333.60	\$ 2,637,807.56	\$ 2,980,284.48	\$ 2,986,659.96	\$ 2,239,994.97
Net Present Value	\$ 8,541,165.05														

Run Scenario Analysis

Click Here To Calculate For A Different Project

Microsoft Excel interface showing the ribbon (Home, Layout, Tables, Charts, SmartArt, Formulas, Data, Review) and the formula bar (A17). The ribbon includes options for Edit, Font (Calibri, 11), Alignment (Wrap Text), Number (General), Format (Currency 2, Normal 2, Percent 2), Cells (Insert, Delete, Format), and Themes. The search bar contains "Search in Sheet".

CASH FLOW STATEMENT AND NPV CALCULATIONS															
INDICATION 1	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028
Sales after launching	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 150,000,000.00	\$ 300,000,000.00	\$ 450,000,000.00	\$ 600,000,000.00	\$ 600,000,000.00
Manufacturing of sold goods	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,672,500.00	\$ 10,445,000.00	\$ 15,667,500.00	\$ 20,890,000.00	\$ 20,890,000.00
Gross profit	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 144,327,500.00	\$ 289,555,000.00	\$ 434,332,500.00	\$ 579,110,000.00	\$ 579,110,000.00
Clinical trial costs (clinical)	\$ 750,000.00	\$ 750,000.00	\$ 1,875,000.00	\$ 1,875,000.00	\$ 1,875,000.00	\$ 1,885,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ -	\$ -	\$ -	\$ -	\$ -
Clinical trial costs (manufacturing)	\$ 825,000.00	\$ 378,000.00	\$ 1,085,000.00	\$ 635,000.00	\$ 635,000.00	\$ 635,000.00	\$ 1,470,000.00	\$ 1,020,000.00	\$ 1,020,000.00	\$ 1,020,000.00	\$ -	\$ -	\$ -	\$ -	\$ -
Staff costs	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00
Estate / facility costs	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 150,000.00	\$ 150,000.00	\$ 150,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00
Sales and marketing costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00
Equipment/Logistic/Other costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00
EBIT (Earning before income tax)	\$ -3,040,000.00	\$ -2,593,000.00	\$ -4,425,000.00	\$ -3,975,000.00	\$ -3,975,000.00	\$ -3,985,000.00	\$ -7,295,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ 140,642,500.00	\$ 285,870,000.00	\$ 430,647,500.00	\$ 575,425,000.00	\$ 575,425,000.00
Taxable Income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 140,642,500.00	\$ 285,870,000.00	\$ 430,647,500.00	\$ 575,425,000.00	\$ 575,425,000.00
Corporate tax rate %	15%														
EBIAT = Cash flow	\$ -3,040,000.00	\$ -2,593,000.00	\$ -4,425,000.00	\$ -3,975,000.00	\$ -3,975,000.00	\$ -3,985,000.00	\$ -7,295,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ 119,546,125.00	\$ 242,989,500.00	\$ 366,050,375.00	\$ 489,111,250.00	\$ 489,111,250.00
Terminal value															\$ 5,455,947.80
Discount value (R&D risk)				0.93	0.93	0.93	0.93	0.51	0.51	0.51	0.51	0.34	0.34	0.34	0.34
Discount value (cost of capital %)		0.750	0.563	0.422	0.316	0.237	0.178	0.133	0.100	0.075	0.056	0.042	0.032	0.024	0.018
Discounted Cash Flows	\$ -2,280,000.00	\$ -1,458,562.50	\$ -1,736,121.09	\$ -1,169,674.80	\$ -877,256.10	\$ -659,597.28	\$ -498,080.77	\$ -350,517.09	\$ -262,887.82	\$ -197,165.86	\$ 1,730,333.60	\$ 2,637,807.56	\$ 2,980,284.48	\$ 2,986,659.96	\$ 2,239,994.97
Net Present Value	\$ 8,541,165.05														

Kun Scenario Analysis

Click Here To Calculate For A Different Project

Microsoft Excel ribbon showing tabs: Home, Layout, Tables, Charts, SmartArt, Formulas, Data, Review. The ribbon includes various toolbars for editing, font, alignment, number, format, and cells. The search bar at the top right contains the text "Search in Sheet".

CASH FLOW STATEMENT AND NPV CALCULATIONS															
INDICATION 1	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028
Sales after launching	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 150,000,000.00	\$ 300,000,000.00	\$ 450,000,000.00	\$ 600,000,000.00	\$ 600,000,000.00
Manufacturing of sold goods	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 5,672,500.00	\$ 10,445,000.00	\$ 15,667,500.00	\$ 20,890,000.00	\$ 20,890,000.00
Gross profit	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 144,327,500.00	\$ 289,555,000.00	\$ 434,332,500.00	\$ 579,110,000.00	\$ 579,110,000.00
Clinical trial costs (clinical)	\$ 750,000.00	\$ 750,000.00	\$ 1,875,000.00	\$ 1,875,000.00	\$ 1,875,000.00	\$ 1,885,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ 3,750,000.00	\$ -	\$ -	\$ -	\$ -	\$ -
Clinical trial costs (manufacturing)	\$ 825,000.00	\$ 825,000.00	\$ 1,085,000.00	\$ 1,085,000.00	\$ 1,085,000.00	\$ 1,085,000.00	\$ 1,470,000.00	\$ 1,470,000.00	\$ 1,470,000.00	\$ 1,470,000.00	\$ -	\$ -	\$ -	\$ -	\$ -
Staff costs	\$ 802,500.00	\$ 802,500.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,365,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 1,575,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00	\$ 2,885,000.00
Estate / facility costs	\$ -	\$ -	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 100,000.00	\$ 150,000.00	\$ 150,000.00	\$ 150,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00	\$ 250,000.00
Sales and marketing costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00	\$ 350,000.00
Equipment/Logistic/Other costs	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00	\$ 200,000.00
EBIT (Earning before income tax)	\$ -2,477,500.00	\$ -2,030,500.00	\$ -4,425,000.00	\$ -3,975,000.00	\$ -3,975,000.00	\$ -3,985,000.00	\$ -7,295,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ 140,642,500.00	\$ 285,870,000.00	\$ 430,647,500.00	\$ 575,425,000.00	\$ 575,425,000.00
Taxable Income	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 140,642,500.00	\$ 285,870,000.00	\$ 430,647,500.00	\$ 575,425,000.00	\$ 575,425,000.00
Corporate tax rate %	15%														
EBIAT = Cash flow	\$ -2,477,500.00	\$ -2,030,500.00	\$ -4,425,000.00	\$ -3,975,000.00	\$ -3,975,000.00	\$ -3,985,000.00	\$ -7,295,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ -6,845,000.00	\$ 119,546,125.00	\$ 242,989,500.00	\$ 366,050,375.00	\$ 489,111,250.00	\$ 489,111,250.00
Terminal value															\$ 5,455,947.89
Discount value (R&D risk)			0.93	0.93	0.93	0.93	0.51	0.51	0.51	0.51	0.34	0.34	0.34	0.34	0.34
Discount value (cost of capital %)		0.750	0.563	0.422	0.316	0.237	0.178	0.133	0.100	0.075	0.056	0.042	0.032	0.024	0.018
Discounted Cash Flows	\$ -1,858,125.00	\$ -1,142,156.25	\$ -1,736,121.09	\$ -1,169,674.80	\$ -877,256.10	\$ -659,597.28	\$ -498,080.77	\$ -350,517.09	\$ -262,887.82	\$ -197,165.86	\$ 1,730,333.60	\$ 2,637,807.56	\$ 2,980,284.48	\$ 2,986,659.96	\$ 2,239,994.97
Net Present Value	\$ 9,279,446.30														

Run Scenario Analysis

Click Here To Calculate For A Different Project